Click here for slides on this topic


An investigational compound of the GLP-1 receptor agonist class for the treatment of type 2 diabetes
The following content matched the glossary term: Lixisenatide

Better Glucose Control With Liraglutide Over Lixisenatide


Liraglutide lowers A1C more than lixisenatide in a head-to-head study of type 2 diabetes patients presented at EASD 2015. Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist


In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association


Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

Slide Library Results

Search Results for: Lixisenatide Slides Found: 2
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI